Floatz logo

PANITUMUMAB

Unresectable Malignant Solid Neoplasm

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

58 Active assets in the Unresectable Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Neratinib Maleate
National Cancer Institute (NCI)
Phase 2B
Eloxatin
National Cancer Institute (NCI)
Phase 2B
Olaparib
National Cancer Institute (NCI)
Phase 2B
Bet Bromodomain Inhibitor Zen-3694
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

PANITUMUMAB is also rated in:

neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →